For research use only. Not for therapeutic Use.
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].
Catalog Number | I043707 |
CAS Number | 56961-10-5 |
Synonyms | 5-chloro-N-(3-chloro-4-nitrophenyl)-2-hydroxybenzamide |
Molecular Formula | C13H8Cl2N2O4 |
Purity | ≥95% |
InChI | InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-8-2-3-11(17(20)21)10(15)6-8/h1-6,18H,(H,16,19) |
InChIKey | FKLGWJUBUPDJJI-UHFFFAOYSA-N |
SMILES | C1=CC(=C(C=C1NC(=O)C2=C(C=CC(=C2)Cl)O)Cl)[N+](=O)[O-] |
Reference | [1]. Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295. |